[go: up one dir, main page]

DK1389100T3 - Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer - Google Patents

Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer

Info

Publication number
DK1389100T3
DK1389100T3 DK02769765T DK02769765T DK1389100T3 DK 1389100 T3 DK1389100 T3 DK 1389100T3 DK 02769765 T DK02769765 T DK 02769765T DK 02769765 T DK02769765 T DK 02769765T DK 1389100 T3 DK1389100 T3 DK 1389100T3
Authority
DK
Denmark
Prior art keywords
stress
treating
protein kinase
kinase inhibitors
activated protein
Prior art date
Application number
DK02769765T
Other languages
Danish (da)
English (en)
Inventor
Lisa D Aimone
Robert L Hudkins
Mathew S Miller
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of DK1389100T3 publication Critical patent/DK1389100T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK02769765T 2001-05-16 2002-05-16 Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer DK1389100T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29122701P 2001-05-16 2001-05-16
US10/146,680 US7018999B2 (en) 2001-05-16 2002-05-15 Methods for the treatment and prevention of pain
PCT/US2002/015667 WO2002092065A2 (fr) 2001-05-16 2002-05-16 Nouvelles methodes de traitement et de prevention de la douleur

Publications (1)

Publication Number Publication Date
DK1389100T3 true DK1389100T3 (da) 2008-12-08

Family

ID=26844179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02769765T DK1389100T3 (da) 2001-05-16 2002-05-16 Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer

Country Status (12)

Country Link
US (1) US7018999B2 (fr)
EP (1) EP1389100B1 (fr)
JP (1) JP2004534751A (fr)
AR (1) AR035971A1 (fr)
AT (1) ATE410201T1 (fr)
AU (1) AU2002342715A1 (fr)
CA (1) CA2447091C (fr)
DE (1) DE60229233D1 (fr)
DK (1) DK1389100T3 (fr)
ES (1) ES2314101T3 (fr)
MX (1) MXPA03010451A (fr)
WO (1) WO2002092065A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
JP2012509282A (ja) 2008-11-19 2012-04-19 セファロン、インク． インダゾロ［５，４−ａ］ピロロ［３，４−ｃ］カルバゾール化合物の新しい形態
US11040947B2 (en) 2017-03-22 2021-06-22 The Research Foundation For The State University Of New York Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1381031A (en) * 1920-01-19 1921-06-07 Thompson James Dumping-wagon
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
AU3064992A (en) 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE69409641T2 (de) * 1993-05-28 1998-11-26 Cephalon, Inc., West Chester, Pa. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5534426A (en) * 1993-07-19 1996-07-09 The Regents Of The University Of California Oncoprotein protein kinase
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5599808A (en) * 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
EP0912184B1 (fr) 1996-06-25 2002-09-25 Cephalon, Inc. Utilisation du derive de k-252a dans le traitement de troubles du systeme nerveux peripherique ou central, et de l'hyperproduction de cytokines
EP1044203B1 (fr) 1997-12-31 2003-03-12 Cephalon, Inc. Derives 3'-epimeres de k-252a
ATE212552T1 (de) 1998-04-17 2002-02-15 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
GB9811624D0 (en) 1998-05-29 1998-07-29 Merck Sharp & Dohme Therapeutic use
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
NZ509612A (en) 1998-08-26 2003-10-31 Cephalon Inc Modulating multiple lineage kinase proteins and screening compounds which modulate multiple lineage kinase proteins
BR9916324A (pt) 1998-12-17 2001-10-02 Hoffmann La Roche 4,5-pirazinoxindóis como inibidores de proteìna quinase
ATE253062T1 (de) 1998-12-17 2003-11-15 Hoffmann La Roche 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
JP2002532493A (ja) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋプロテインキナーゼ阻害剤としての４−アリールオキシインドール
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
EP1175399B1 (fr) 1999-04-23 2009-03-11 Vertex Pharmaceuticals Incorporated Inhibiteurs des c-jun n-terminal kinases (jnk)
WO2000075118A1 (fr) 1999-06-03 2000-12-14 Vertex Pharmaceuticals Incorporated INHIBITEURS DE KINASES c-JUN N-TERMINALES (JNK)
EP1196167B1 (fr) 1999-07-02 2006-04-19 Stuart A. Lipton Utilisation des inhibiteurs p38 MAPK pour des maladies ophthalmiques
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
CZ2002534A3 (cs) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
CN1304375C (zh) 1999-08-19 2007-03-14 信号药品公司 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1289523A1 (fr) 2000-06-01 2003-03-12 Merck & Co., Inc. Utilisation de derives de (phenyle disubstitue)-pyrimidinyl-imidazole comme inhibiteurs de jnk
JP2004537497A (ja) 2000-11-08 2004-12-16 ザ ジェネラル ホスピタル コーポレーション 疼痛を阻害するための方法
ES2307667T3 (es) 2000-12-05 2008-12-01 Vertex Pharmaceuticals Incorporated Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas.

Also Published As

Publication number Publication date
WO2002092065A3 (fr) 2003-07-31
EP1389100A2 (fr) 2004-02-18
AR035971A1 (es) 2004-07-28
US20030087899A1 (en) 2003-05-08
WO2002092065A2 (fr) 2002-11-21
CA2447091C (fr) 2012-03-27
JP2004534751A (ja) 2004-11-18
CA2447091A1 (fr) 2002-11-21
US7018999B2 (en) 2006-03-28
MXPA03010451A (es) 2004-05-05
EP1389100B1 (fr) 2008-10-08
AU2002342715A1 (en) 2002-11-25
ES2314101T3 (es) 2009-03-16
ATE410201T1 (de) 2008-10-15
DE60229233D1 (de) 2008-11-20
HK1062806A1 (en) 2004-11-26

Similar Documents

Publication Publication Date Title
ATE414699T1 (de) Inhibitoren von tyrosinkinasen
NO20020635D0 (no) Proteinpolymeriseringsinhibitorer og fremgangsmåter for anvendelse
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NO20035604D0 (no) Skiferhydreringsinhiberingsmiddel og fremgangsmåte for anvendelse derav
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
NO20011964L (no) Brönnbehandlingsfluider og fremgangsmåter for anvendelse derav
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
DK1997809T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS8037A (is) P38-hindrar og aðferðir til notkunar þeirra
EP1534268A4 (fr) Inhibiteurs de la tyrosine kinase
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1590360T3 (da) Fremgangsmåde til fremstilling af inhibitorer af nukleosidphosphorylaser og nukleosidaser
EP1539248A4 (fr) Inhibiteurs de l'interaction proteine-proteine s100-p53 et methode d'inhibition du cancer utilisant lesdits inhibiteurs
NO20033429L (no) Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)
EP1651599A4 (fr) Inhibiteurs des tyrosine kinases
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
EP1496897A4 (fr) Inhibiteurs de tyrosines kinases
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1389100T3 (da) Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
DK1228026T3 (da) 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
DK1244662T3 (da) Pyridazinoquinolinderivater og fremgangsmåde til behandling af smerter